Live Bacterial Vaccines--a Review and Identification of Potential Hazards

Overview

Journal Microb Cell Fact

Publisher Biomed Central

Specialties Biotechnology
Microbiology

Date 2006 Jun 27

PMID 16796731

Citations 67

Authors

Ann Detmer

Jacob Glenting

Affiliations

Soon will be listed here.

Abstract

The use of live bacteria to induce an immune response to itself or to a carried vaccine component is an attractive vaccine strategy. Advantages of live bacterial vaccines include their mimicry of a natural infection, intrinsic adjuvant properties and their possibility to be administered orally. Derivatives of pathogenic and non-pathogenic food related bacteria are currently being evaluated as live vaccines. However, pathogenic bacteria demands for attenuation to weaken its virulence. The use of bacteria as vaccine delivery vehicles implies construction of recombinant strains that contain the gene cassette encoding the antigen. With the increased knowledge of mucosal immunity and the availability of genetic tools for heterologous gene expression the concept of live vaccine vehicles gains renewed interest. However, administration of live bacterial vaccines poses some risks. In addition, vaccination using recombinant bacteria results in the release of live recombinant organisms into nature. This places these vaccines in the debate on application of genetically modified organisms. In this review we give an overview of live bacterial vaccines on the market and describe the development of new live vaccines with a focus on attenuated bacteria and food-related lactic acid bacteria. Furthermore, we outline the safety concerns and identify the hazards associated with live bacterial vaccines and try to give some suggestions of what to consider during their development.

Citing Articles

Bacillus subtilis surface display technology: applications in bioprocessing and sustainable manufacturing.

Bahrulolum H, Ahmadian G Biotechnol Biofuels Bioprod. 2025; 18(1):34.

PMID: 40089785 DOI: 10.1186/s13068-025-02635-4.

Invasions of Host-Associated Microbiome Networks.

Murall C, Abbate J, Touzel M, Allen-Vercoe E, Alizon S, Froissart R Adv Ecol Res. 2024; 57:201-281.

PMID: 39404686 PMC: 7616576. DOI: 10.1016/bs.aecr.2016.11.002.

An unnatural amino acid dependent, conditional Pseudomonas vaccine prevents bacterial infection.

Pigula M, Lai Y, Koh M, Diercks C, Rogers T, Dik D Nat Commun. 2024; 15(1):6766.

PMID: 39117651 PMC: 11310302. DOI: 10.1038/s41467-024-50843-7.

Engineering Toxoplasma gondii secretion systems for intracellular delivery of multiple large therapeutic proteins to neurons.

Bracha S, Johnson H, Pranckevicius N, Catto F, Economides A, Litvinov S Nat Microbiol. 2024; 9(8):2051-2072.

PMID: 39075233 PMC: 11306108. DOI: 10.1038/s41564-024-01750-6.

Mucosal Administration of Surface-Displayed HA1 Induces Protective Immune Responses against Avian Influenza A Virus in Mice.

Huynh D, Chathuranga W, Chathuranga K, Lee J, Kim C J Microbiol Biotechnol. 2023; 34(3):735-745.

PMID: 37915251 PMC: 11016770. DOI: 10.4014/jmb.2307.07040.

References

Pelto L, Isolauri E, Lilius E, Nuutila J, Salminen S . Probiotic bacteria down-regulate the milk-induced inflammatory response in milk-hypersensitive subjects but have an immunostimulatory effect in healthy subjects. Clin Exp Allergy. 1999; 28(12):1474-9. DOI: 10.1046/j.1365-2222.1998.00449.x. View

Lindberg A . Vaccination against enteric pathogens: from science to vaccine trials. Curr Opin Microbiol. 1999; 1(1):116-24. DOI: 10.1016/s1369-5274(98)80151-3. View

Mercenier A, Grangette C . Lactic acid bacteria as live vaccines. Curr Issues Mol Biol. 2001; 2(1):17-25. View

Oh Y, Kim J, Hwang T, Ko J, Kim J, Yang J . Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. Vaccine. 2001; 19(31):4519-25. DOI: 10.1016/s0264-410x(01)00188-8. View

Shata M, Hone D . Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity. J Virol. 2001; 75(20):9665-70. PMC: 114537. DOI: 10.1128/JVI.75.20.9665-9670.2001. View

Kruisselbrink A, Havenith C, Thole J, Janssen R . Recombinant Lactobacillus plantarum inhibits house dust mite-specific T-cell responses. Clin Exp Immunol. 2001; 126(1):2-8. PMC: 1906181. DOI: 10.1046/j.1365-2249.2001.01642.x. View

DOERFLER W, Hohlweg U, Muller K, Remus R, Heller H, Hertz J . Foreign DNA integration--perturbations of the genome--oncogenesis. Ann N Y Acad Sci. 2001; 945:276-88. DOI: 10.1111/j.1749-6632.2001.tb03896.x. View

Ledwith B, Manam S, Troilo P, Barnum A, Pauley C, Griffiths 2nd T . Plasmid DNA vaccines: assay for integration into host genomic DNA. Dev Biol (Basel). 2001; 104:33-43. View

Bumann D, Metzger W, Mansouri E, Palme O, Wendland M, HURWITZ R . Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine. 2001; 20(5-6):845-52. DOI: 10.1016/s0264-410x(01)00391-7. View

10.

Yuhua L, Kunyuan G, Hui C, Yongmei X, Chaoyang S, Xun T . Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium. Int J Cancer. 2001; 94(3):438-43. DOI: 10.1002/ijc.1489. View

11.

Tvinnereim A, Hamilton S, Harty J . CD8(+)-T-cell response to secreted and nonsecreted antigens delivered by recombinant Listeria monocytogenes during secondary infection. Infect Immun. 2001; 70(1):153-62. PMC: 127606. DOI: 10.1128/IAI.70.1.153-162.2002. View

12.

Shimoji Y, Oishi E, Kitajima T, Muneta Y, Shimizu S, Mori Y . Erysipelothrix rhusiopathiae YS-1 as a live vaccine vehicle for heterologous protein expression and intranasal immunization of pigs. Infect Immun. 2001; 70(1):226-32. PMC: 127599. DOI: 10.1128/IAI.70.1.226-232.2002. View

13.

Christensen H, Frokiaer H, Pestka J . Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol. 2001; 168(1):171-8. DOI: 10.4049/jimmunol.168.1.171. View

14.

Rayevskaya M, Kushnir N, Frankel F . Safety and immunogenicity in neonatal mice of a hyperattenuated Listeria vaccine directed against human immunodeficiency virus. J Virol. 2001; 76(2):918-22. PMC: 136818. DOI: 10.1128/jvi.76.2.918-922.2002. View

15.

Zheng C, Xie P, Chen Y . Recombinant Mycobacterium bovis BCG producing the circumsporozoite protein of Plasmodium falciparum FCC-1/HN strain induces strong immune responses in BALB/c mice. Parasitol Int. 2002; 51(1):1-7. DOI: 10.1016/s1383-5769(01)00094-0. View

16.

Al-Mariri A, Tibor A, Lestrate P, Mertens P, De Bolle X, Letesson J . Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen. Infect Immun. 2002; 70(4):1915-23. PMC: 127831. DOI: 10.1128/IAI.70.4.1915-1923.2002. View

17.

Kotloff K, Taylor D, Sztein M, Wasserman S, Losonsky G, Nataro J . Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun. 2002; 70(4):2016-21. PMC: 127867. DOI: 10.1128/IAI.70.4.2016-2021.2002. View

18.

Vecino W, Morin P, Agha R, Jacobs Jr W, Fennelly G . Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV. Immunol Lett. 2002; 82(3):197-204. DOI: 10.1016/s0165-2478(02)00043-3. View

19.

Kruger C, Hu Y, Pan Q, Marcotte H, Hultberg A, Delwar D . In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat Biotechnol. 2002; 20(7):702-6. DOI: 10.1038/nbt0702-702. View

20.

Belloni C, Avanzini M, De Silvestri A, Martinetti M, Pasi A, Coslovich E . No evidence of autoimmunity in 6-year-old children immunized at birth with recombinant hepatitis B vaccine. Pediatrics. 2002; 110(1 Pt 1):e4. DOI: 10.1542/peds.110.1.e4. View